+ 08.10.2021 - Dr Robert Hess: Booster jabs are contributing to the individualization of the vaccination concept: Weighing up the potential side-effects of the Covid-19 vaccines and deciding the “price” we are willing to pay.
As winter approaches in the northern hemisphere, booster vaccinations are being rolled out with the aim of giving maximum protection to the elderly, the immunocompromised and professionals exposed to the virus. The administration of booster jabs against Covid-19 is a new concept and one that is likely to be with us for the foreseeable future, as the efficacy of the vaccines against Covid-19 wears off over time. According to the manufacturer of the Pfizer/BioNTech vaccine, it loses approximately six percent of its effectiveness every two months, but our experience has shown that this is a conservative estimate.
+ 05.10.2021 - Dr Robert Hess: Corona drug molnupiravir significantly reduces number of severe cases of disease and raises hopes, says manufacturer.
Merck Sharp and Dohme (MSD), the US pharmaceutical giant based in Kenilworth, New York, last week reported positive results from a Phase III trial of its new corona drug, molnupiravir. The manufacturer claim that it alleviates the course of the COVID-19 disease and halves the risk of hospitalization or death from a coronavirus infection. The potentially groundbreaking results promise a new way of treating COVID-19 and herald the first of hopefully many more antiviral drugs.
+ 29.09.2021 - Dr Robert Hess: FDA approves booster dose of Pfizer-BioNTech vaccine for the over-65s and for vulnerable categories but not yet for the wider population.
The issue of booster vaccination has risen high on the agenda, and every country is taking a different approach to it. Israel, Austria and Russia are already offering booster jabs to the general population, whereas Belgium, the United Kingdom, Denmark, Finland, France, Ireland, Italy, Spain and Sweden are restricting them to the immunocompromised or elderly. Germany will reach its own national decision in early October, and in the United States, the FDA announced last week that it had approved boosters, albeit on a more restrictive basis than had been expected.
+ 21.09.2021 - Dr Robert Hess: A first step in the right direction: BioNTech introduces the “individualization” concept into vaccination strategy.
Where are we now, almost two years into the pandemic? Nine months after the first vaccines for the prevention of Covid-19 were approved, are there any conclusions that can be reliably drawn? Since December 2020, 2.39 billion people worldwide have been vaccinated against Covid-19, with a total of 5.82 billion doses having been administered. Just under 30% of the world’s population has thus been fully vaccinated, and in the United States that figure has now passed the 50% mark.
+ 16.09.2021 - Dr Robert Hess: Current status and news of new concepts such as antibody therapy and vaccination by inhalation against COVID-19 infection.
Dr Robert Hess has a special interest in this topic, because for some of our premium members the conventional vaccination against Covid-19 is not an option or even can be counterproductive. We see these new concepts as possible solutions for additional protection against coronavirus infection without the need for vaccination. In certain cases, monoclonal antibodies (MAK) are considered to be a promising drug against severe disease progression in SARS-CoV-2 infection and have been used in the clinical setting for some time. In this context, we are particularly interested in the question of whether and, if so, when antibody therapy might also be used in the context of prophylaxis against a covid infection.
+ 14.09.2021 - Dr Robert Hess: Update on new mutations and what you need to know about COVID-19 variants.
As experts in the field of human and molecular genetics and thus also on the topic of mutations, we provide regular updates and forecasts of where the pandemic might be heading. Recently, new discoveries have come into the frame, so we have summarized these findings for you and added our own assessment.
+ 08.09.2021 - Dr Robert Hess: Second attempt for CureVac: Modified vaccine developed in collaboration with GSK is in preclinical testing.
CureVac’s first-generation vaccine candidate CVnCoV unfortunately fell by the wayside in mid-June after failing to meet the statistical criteria for success, but there is now news regarding a modified second-generation vaccine candidate, which CureVac has developed in collaboration with British pharmaceutical giant GSK.
+ 03.09.2021 - Dr Robert Hess: Recent studies have established a strong link between the presence of autoantibodies against interferon-I and a severe progression of disease after infection with SARS-CoV-2.
As we have explained in previous Keynotes, our body’s own interferon system plays an important role in the activation and modulation of the immune defenses. In this update, we will focus on what happens when there is a failure to activate the type I interferons (IFN-I) and on the risks that this poses. IFN-I is of immense importance in relation to the body’s own virus defense and thus highly relevant in the context of the SARS-CoV-2 pandemic.
+ 25.08.2021 - Dr Robert Hess: FDA grants full approval to the Pfizer/BioNTech COVID-19 vaccine – What exactly does full FDA approval of a vaccine mean?
The Pfizer/BioNTech COVID-19 vaccine first received Emergency Use Authorization (EUA) from the U.S. authorities in mid-December 2020 for administration to persons aged 16 and older. On Monday, the FDA announced that it has now granted full approval. The vaccine has thus become the first to receive FDA approval for use against coronavirus. More are expected to follow in the coming weeks and months. Emergency Use Authorization continues to apply for use on adolescents aged 12 to 15 years and for administration as a third booster dose to immunocompromised individuals. Further monitoring of the vaccine’s safety and efficacy remains mandatory, even after approval, and will be carried out assiduously.
+ 12.08.2021 - Differing opinions about the Lambda variant: Super mutant, successor to Delta or damp squib?
For the first time since the SARS-CoV-2 Task Force was established 18 months ago, a difference of opinion has arisen, specifically with regard to the Lambda variant. What everyone agrees on is that the Lambda or C.37 variant is clearly more contagious than the original Wuhan strain. In addition, it is much more resistant to antibodies, and the existing vaccines therefore have a reduced efficacy against it. The reason for this is three mutations in the spike protein, which render it less susceptible to neutralization by antibodies. Added to which there are two mutations that make the variant itself more infectious.
+ 20.07.2021 - The skepticism of Dr Robert Hess regarding the efficacy of all previous vaccines against the Delta variant has been confirmed by the announcement from BioNTech/Pfizer that they are working on a vaccine that will specifically target this mutant.
The Delta variant of the novel coronavirus, which is causing concern across the whole of Europe, is now starting to show up in America. BioNTech and its manufacturing partner Pfizer announced last Friday that they are developing an updated version of the Pfizer/BioNTech Covid-19 vaccine that will target the complete spike protein of this latest variant. They also stated that the first batch of this vaccine consisting of approximately 20,000 doses has already been produced at the Mainz plant in Germany. The clinical trials are due to start in August this year.
+ 09.07.2021 - The SARS-CoV-2 T-Cell immunity analysis is to be integrated into our Covid-19 Immunization Program for clients with immediate effect.
So far, we have been testing only one of the two immunity pillars, namely antibody production. In addition to checking the full range of antibodies, Dr Robert Hess goes far beyond the generally applied classification to differentiate between the neutralizing antibodies and identify efficacy classes – low, medium and high – plus ADE antibodies which may even have the undesired effect of amplifying an infection. From now on, we will also be measuring the second Covid-19 immune pillar – namely T cell immunity – in great detail. For this purpose, we have upgraded our Covid-19 Immunization Program with the inclusion of the new SARS-CoV-2 T-Cell immunity analysis.
+ 09.07.2021 - The SARS-CoV-2 T-Cell immunity analysis is to be integrated into the Covid-19 Immunization Program.
So far, we have been testing only one of the two immunity pillars, namely antibody production. In addition to checking the full range of antibodies, we at Salvagene go far beyond the generally applied classification to differentiate between the neutralizing antibodies and identify efficacy classes – low, medium and high – plus ADE antibodies which may even have the undesired effect of amplifying an infection. From now on, we will also be measuring the second Covid-19 immune pillar – namely T cell immunity – in great detail. For this purpose, we have upgraded our Covid-19 Immunization Program with the inclusion of the new SARS-CoV-2 T-Cell immunity analysis.
+ 23.06.2021 - CureVac were our great hope. They reached for the stars – and came back down with a bump.
Though the news was not entirely unexpected, we regret to report that the breakthrough vaccine promised by CureVac will now not be forthcoming. There are a number of reasons for this, but the main factor was the high demands that CureVac itself placed on the product. The aim was to develop a vaccine that was as natural as possible – ideally the most natural vaccine to date. In the end, it was the much-debated issue of vaccine-induced side-effects and long-term effects that thwarted their endeavor.
+ 19.06.2021 - Dr Robert Hess asks the vital question: "How long does the protection afforded by vaccination last?" That can only be answered when enough time has elapsed for results to come in.
There is one thing we can be certain of, however, namely that the protection afforded by vaccines does not live up to the claims made by their manufacturers. We strongly disagree with the assertion that “vaccine protection will remain at the same high level for approximately one year, so that we can get into an annual vaccination cycle like the one we have for influenza.” This is the reason why we set up our SARS-CoV-2 Antibody Profile Monitoring for Premium clients at the start of this year, measuring levels of SARS-CoV-2 antibodies as well as T-helper cells specific to SARS-CoV-2 and thereby covering both pillars of the immune response.
+ 18.06.2021 - The Delta variant is not the dreaded super mutant, but it may be a game-changer in a negative sense.
In India, the Delta variant has been responsible for a sharp increase in the number of infections, illnesses and fatalities. The health system there is at breaking point. In the meantime, the Delta variant has also been discovered in other parts of the world, especially in the UK, which is a country where virus variants are monitored with exemplary thoroughness. It is expected that the Delta variant will supplant Alpha (B.1.1.7), which has been the most widespread variant so far. According to official data, Delta is currently present in nine out of ten samples sent for analysis.
+ 11.06.2021 - We are now several months into the vaccination campaign, and it is clear to us from our own SARS-CoV-2 antibody and immunization testing that the track record of the vaccines is very disappointing, with more side-effects than originally expected.
We therefore intend to have a personalized vaccine combination in place for 2022.
In contrast to the phase 3 data published by the various vaccine manufacturers, some of which claim headline rates of more than 90% efficacy, the test results that have come back from our clients indicate none of the vaccines has achieved this sort of success. Based on the clinical data and biochemical evaluations that we carry out at regular three-monthly intervals, we conclude that the levels actually attained are considerably lower. Antibody production and quality in particular reveal a significantly lower immunization status. This applies to all vaccines.
+ 01.06.2021 - On 30th March 2021, the WHO Commission of Inquiry issued a statement to the effect that a laboratory accident as the cause of the pandemic was “extremely unlikely”. The skepticism we expressed at the time about their findings is now being vindicated.
Therefore Dr Robert Hess intends to have a personalized vaccine combination in place for 2022.
At the time, we came in for considerable criticism for our assessment that the probability of a laboratory accident having released the virus was around 60%, and we were even accused of stirring up a conspiracy theory.